Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
Abstract Tofactinib is a JAK inhibitor approved for ulcerative colitis in humans. Despite of its’ proven effectiveness in humans, mechanistic data are scarce on the effectiveness of Tofactinib in experimental colitis in mice. We induced experimental colitis by transfer of CD4+CD25− isolated T cells...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-30616-w |